<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960424</url>
  </required_header>
  <id_info>
    <org_study_id>AD-2017C3-9185</org_study_id>
    <nct_id>NCT03960424</nct_id>
  </id_info>
  <brief_title>Diabetes Management Program for Hispanic/Latino</brief_title>
  <official_title>Diabetes Management Program for Hispanic/Latino</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare Diabetes Telemonitoring to comprehensive outpatient management (COM) on critical&#xD;
      patient-centered outcomes, including HbA1c.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a multiphase mixed method, Comparative Effectiveness Research&#xD;
      Randomized Control Trial (CER RCT) to:&#xD;
&#xD;
      Specific Aim 1: Assess usability of an evidence-based DTM intervention utilizing a Community&#xD;
      Based Participatory Research (CBPR) approach and adapt it to facilitate acceptability and&#xD;
      feasibility in a population of H/L patients with T2D, and their caregivers and providers.&#xD;
&#xD;
      Specific Aim 2: Assess whether H/L patients receiving DTM attain significantly improved&#xD;
      patient-centered outcomes compared to COM, through a CER RCT. Expected outcomes include&#xD;
      improved diabetes quality of life (QoL), glucose management (GM), blood pressure (BP),&#xD;
      cholesterol, medication adherence, and diabetes self-efficacy (SE), and reduced diabetes&#xD;
      distress, problem areas in diabetes (PAID), inpatient utilization, unscheduled T2D physician&#xD;
      visits and sick days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Mixed Methods Design, incorporating adaptations before RCT trial commencement.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>6 months</time_frame>
    <description>HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 months</time_frame>
    <description>Hemoglobin A1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Number of hypoglycemia episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>6 months</time_frame>
    <description>Adherence to Refills and Medications - Diabetes (ARMS-D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes self-efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes Self-Efficacy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAID</measure>
    <time_frame>6 months</time_frame>
    <description>Problem Areas in Diabetes Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>6 months</time_frame>
    <description>lbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in cholesterol over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes-39 is a validated instrument specifically designed to measure quality of life for diabetes patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetes Telemonitoring (DTM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for Type 2 Diabetes (T2D), uses smart devices to share information between patients, caregivers, and clinicians. DTM includes:1) weekly real time &quot;virtual&quot; visit between patient and clinician 2) vital signs monitoring/interpretation 3) diabetes management 4) patient interactive educational videos and &quot;teach back&quot; quizzes, reinforcing self-management strategies 5) a caregiver app with supportive capability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comprehensive Outpatient Management (COM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comprehensive Outpatient Management (COM) is the most realistic evidence-based comparator, in that it is the most frequently recommended and used option for US T2D patients. COM, like DTM, is consistent with the 2018 American Diabetes Association (ADA) Standards which include, but are not limited to, past medical and family history, social history, medications, screening, physical examination, laboratory evaluation, etc.Patients are instructed to monitor blood glucose (within physician recommendations), and have routine or &quot;well&quot; visits every 3 months. Patients can set appointments with a T2D educator. COM patients will receive monthly calls from the study Registered Nurse (RN) to collect data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comprehensive Outpatient Management</intervention_name>
    <description>Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.</description>
    <arm_group_label>Comprehensive Outpatient Management (COM)</arm_group_label>
    <other_name>COM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diabetes Telemonitoring</intervention_name>
    <description>Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.</description>
    <arm_group_label>Diabetes Telemonitoring (DTM)</arm_group_label>
    <other_name>DTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hispanic patients with a diagnosis of diabetes&#xD;
&#xD;
          -  Speaks English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is not Hispanic&#xD;
&#xD;
          -  Patient does not have a diagnosis of diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee Pekmezaris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Feinstein Institute for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Marbury, CRA</last_name>
    <phone>(516) 465-2776</phone>
    <email>dmarbury@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myia Williams, PhD</last_name>
    <phone>516-600-1485</phone>
    <email>mwilliam26@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Feinstein Institute of Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Pekmezaris, PhD</last_name>
      <phone>516-600-1402</phone>
      <email>rpekmeza@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Myia Williams, PhD</last_name>
      <phone>516-600-1485</phone>
      <email>mwilliam26@northwell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Renee Pekmezaris, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/Prot_SAP_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/ICF_005.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

